Compare · ELV vs PSNL
ELV vs PSNL
Side-by-side comparison of Elevance Health Inc. (ELV) and Personalis Inc. (PSNL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and PSNL operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $87.86B, about 87.3x PSNL ($1.01B).
- Over the past year, ELV is up 6.2% and PSNL is up 64.1% - PSNL leads by 57.9 points.
- PSNL has been more active in the news (11 items in the past 4 weeks vs 4 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 14 for PSNL).
- Company
- Elevance Health Inc.
- Personalis Inc.
- Price
- $404.50-4.68%
- $9.60-1.59%
- Market cap
- $87.86B
- $1.01B
- 1M return
- +5.98%
- +65.52%
- 1Y return
- +6.15%
- +64.10%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 4
- 11
- Recent ratings
- 23
- 14
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Personalis Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.
Latest ELV
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
Latest PSNL
- Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
- CFO AND COO Tachibana Aaron exercised 40,000 shares at a strike of $9.16 and sold $480,400 worth of shares (40,000 units at $12.01) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
- Chief Executive Officer Hall Christopher M sold $1,102,000 worth of shares (100,000 units at $11.02) as part of a pre-agreed trading plan and exercised 100,000 shares at a strike of $1.61 (SEC Form 4)
- CFO AND COO Tachibana Aaron sold $449,292 worth of shares (38,799 units at $11.58) as part of a pre-agreed trading plan and exercised 38,799 shares at a strike of $9.16 (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- SEC Form 144 filed by Personalis Inc.
- Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
- Personalis Inc. filed SEC Form 8-K: Other Events